Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells by Gu, Mancang et al.
Aspirin exerts high anti-cancer activity
in PIK3CA-mutant colon cancer cells
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Gu, M., R. Nishihara, Y. Chen, W. Li, Y. Shi, Y. Masugi, T. Hamada, et
al. 2017. “Aspirin exerts high anti-cancer activity in PIK3CA-mutant
colon cancer cells.” Oncotarget 8 (50): 87379-87389. doi:10.18632/
oncotarget.20972. http://dx.doi.org/10.18632/oncotarget.20972.
Published Version doi:10.18632/oncotarget.20972
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34493234
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Oncotarget87379www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 50), pp: 87379-87389
Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon 
cancer cells 
Mancang Gu1,2, Reiko Nishihara1,3,4,5,6, Yang Chen1,7, Wanwan Li1, Yan Shi1,7, 
Yohei Masugi1, Tsuyoshi Hamada1, Keisuke Kosumi1, Li Liu1,3, Annacarolina da Silva1, 
Jonathan A. Nowak6, Tyler Twombly1, Chunxia Du1, Hideo Koh1, Wenbin Li1, 
Jeffrey A. Meyerhardt8, Brian M. Wolpin8, Marios Giannakis8, Andrew J. Aguirre8, 
Adam J. Bass8,9,10, David A. Drew11,12, Andrew T. Chan11,12, Charles S. Fuchs13,14,15,*, 
Zhi Rong Qian1,6,* and Shuji Ogino1,4,6,*
1Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
2College of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, P.R. China
3Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
4Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
5Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
6 Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and 
Harvard Medical School, Boston, MA, USA
7Medical Oncology Department 2, Chinese People’s Liberation Army General Hospital, Beijing, P.R. China
8Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
9Broad Institute of MIT and Harvard, Cambridge, MA, USA
10Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
11Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
12Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA
13Yale Cancer Center, New Haven, CT, USA
14Department of Medicine, Yale School of Medicine, New Haven, CT, USA
15Smilow Cancer Hospital, New Haven, CT, USA
*These authors contributed equally to this work
Correspondence to: Zhi Rong Qian, email: zhirong_qian@dfci.harvard.edu 
Shuji Ogino, email: shuji_ogino@dfci.harvard.edu
Keywords: anti-tumor effect, colorectal cancer, isogenic cell model, NSAID, PI3K
Received: May 31, 2017    Accepted: August 31, 2017    Published: September 18, 2017
Copyright: Gu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Evidence suggests that nonsteroidal anti-inflammatory drug aspirin 
(acetylsalicylic acid) may improve patient survival in PIK3CA-mutant colorectal 
carcinoma, but not in PIK3CA-wild-type carcinoma. However, whether aspirin directly 
influences the viability of PIK3CA-mutant colon cancer cells is poorly understood. 
We conducted in vitro experiments to test our hypothesis that the anti-proliferative 
activity of aspirin might be stronger for PIK3CA-mutant colon cancer cells than for 
PIK3CA-wild-type colon cancer cells. We measured the anti-proliferative effect of 
aspirin at physiologic concentrations in seven PIK3CA-mutant and six PIK3CA-wild-
type human colon cancer cell lines. After exposure to aspirin, the apoptotic index and 
cell cycle phase of colon cancer cells were assessed. In addition, the effect of aspirin 
was examined in parental SW48 cells and SW48 cell clones with individual knock-in 
PIK3CA mutations of either c.3140A>G (p.H1047R) or c.1633G>A (p.E545K). Aspirin 
induced greater dose-dependent loss of cell viability in PIK3CA-mutant cells than in 
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INTRODUCTION
Colorectal cancer is the second leading cause of 
cancer-related deaths in the U.S. [1], and the prognosis for 
individuals with advanced colorectal cancer remains poor 
[2, 3]. Accumulating evidence indicates that colorectal 
cancer is a heterogeneous group of diseases, and that 
responsiveness to treatment varies from patient to patient 
[4–7]. This heterogeneity necessitates precision medicine 
approaches that take tumor molecular characteristics into 
account in order to predict an individual’s response to a 
specific agent.
Aspirin (acetylsalicylic acid) is one of the most 
commonly used medications worldwide as an effective 
analgesic, antipyretic and cardiovascular prophylactic 
agent. Several observational studies and randomized 
controlled trials have shown that regular use of aspirin 
after a diagnosis of colorectal cancer is associated 
with a superior clinical outcome [8–14]. Randomized 
trials of aspirin for prevention of cardiovascular and 
cerebrovascular events also suggest that regular aspirin 
use has the potential to reduce colorectal cancer incidence 
and mortality [15, 16]. Recently, the U.S. Preventive 
Services Task Force (USPSTF) recommended the use of 
aspirin for prevention of colorectal cancer in individuals at 
a 10% increased risk for cardiovascular disease compared 
with the general population [17], while cautioning against 
the potential harms associated with regular aspirin 
use including gastrointestinal pain and bleeding [18]. 
Therefore, it is of particular interest to identify subgroups 
of individuals who are most likely to benefit from aspirin-
based therapeutic strategies through the development of 
informative tumor biomarkers [14].
In line with this precision medicine approach, 
multiple observational studies of colorectal cancer patients 
have indicated that the beneficial effects of aspirin may 
be stronger for PIK3CA-mutant colorectal cancer than 
for PIK3CA-wild-type tumors [12, 13, 19], though other 
studies have shown alternate findings [20, 21]. PIK3CA 
mutations are observed in approximately 15% to 20% 
of human colorectal carcinomas, and are associated with 
proximal tumor location [22–25] and KRAS mutations 
[26–28]. PIK3CA mutations can activate multiple 
oncogenic pathways, including the phosphatidylinositol-
4,5-bisphosphonate 3-kinase (PI3K)/AKT/MTOR, WNT/
CTNNB1, and NFKB signaling pathways [29–31]. 
Studies have shown that PI3K upregulation also enhances 
prostaglandin-endoperoxide synthase-2 (PTGS2, also 
known as cyclooxygenase-2) activity and prostaglandin E2 
synthesis [32], which promotes cancer cell proliferation 
and inhibits apoptosis [33, 34]. Therefore, we 
hypothesized that the anti-cancer effects of aspirin might 
be stronger for PIK3CA-mutant colon carcinoma cell lines 
than for PIK3CA-wild-type colon carcinoma cell lines. 
To test this hypothesis, we assessed the effect of 
aspirin treatment on cell cycle arrest and apoptosis using 
13 colon cancer cell lines with known PIK3CA mutation 
status and isogenic colon cancer cells with knock-in 
PIK3CA-activating mutations. Additionally, our study 
identified cell models that may serve as ideal in vitro 
models to further clarify the molecular mechanisms of 
aspirin’s anti-tumor effects in PIK3CA-mutant colorectal 
cancer. 
RESULTS
Strong cell viability reduction by aspirin in 
PIK3CA-mutant colon cancer cells
To test the hypothesis that aspirin’s anti-cancer 
effects might differ by PIK3CA mutation status, we 
investigated the anti-proliferative activity of aspirin 
at physiologically attainable concentrations in seven 
PIK3CA-mutant and six PIK3CA-wild-type colon cancer 
cell lines (Table 1) using the 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- 
tetrazolium inner salt (MTS) assay. Initially, we examined 
the effect of a variety of aspirin doses (0, 0.5, 1, 2, 4, 6, 
8, 10, and 12 mM) on cell proliferation after exposure 
to aspirin for 12 to 96 hours in two PIK3CA-mutant 
(HCT15 and HCT116) and PIK3CA-wild-type (SW480 
and SW620) colon cancer cell lines. We found that the 
most prominent effects of aspirin on proliferation occurred 
between 48 and 72 hours of exposure. Therefore, all 
subsequent experiments were performed after treatment 
with aspirin for 48 and 72 hours. The dose-response curves 
of PIK3CA-mutant and PIK3CA-wild-type colon cancer 
cell lines were generated (Figure 1) and the half maximal 
inhibitory concentration (IC50) values of each PIK3CA 
subgroup were compared (Supplementary Figure 1A). 
PIK3CA-wild-type cells after treatment for 48 and 72 hours. Aspirin treatment also 
led to higher proportions of apoptotic cells and G0/G1 phase arrest in PIK3CA-mutant 
cells than in PIK3CA-wild-type cells. Aspirin treatment of isogenic SW48 cells carrying 
a PIK3CA mutation, either c.3140A>G (p.H1047R) or c.1633G>A (p. E545K), resulted 
in a more significant loss of cell viability compared to wild-type controls. Our findings 
indicate that aspirin causes cell cycle arrest, induces apoptosis, and leads to loss of 
cell viability more profoundly in PIK3CA-mutated colon cancer cells than in PIK3CA-
wild-type colon cancer cells. These findings support the use of aspirin to treat patients 
with PIK3CA-mutant colon cancer. 
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PIK3CA-mutant colon cancer cell lines were considerably 
more sensitive to the anti-proliferative effects of aspirin 
than PIK3CA-wild-type cells (Figure 1A). Aspirin did 
not show differential effects according to BRAF or KRAS 
mutation status (Figure 1B). Next, in order to validate that 
PIK3CA-mutant colon cancer cell lines were specifically 
sensitized to aspirin but not to common DNA damaging 
chemotherapeutic agents, we investigated the IC50 values 
of 5-fluorouracil and cisplatin in our thirteen colon 
cancer lines from a compound sensitivity database of the 
Cancer Cell Line Encyclopedia (CCLE) [35]. However, 
no significant differences were found between PIK3CA-
mutant and PIK3CA-wild-type colon cancer cell lines 
(Supplementary Figure 1B). 
Aspirin induces apoptosis and G0/G1 cell cycle 
arrest in PIK3CA-mutant cells
We evaluated the effects of aspirin on induction of 
apoptosis and cell cycle distribution in three PIK3CA-
mutant cell lines (HCT15, HCT116, and SW948) that 
were particularly sensitive to aspirin exposure in the MTS 
assay and three PIK3CA-wild-type colon cancer cell lines 
(COLO205, SW480, and SW620) that were resistant to 
aspirin exposure. Cells were treated with 0, 1, 2.5, and 
5 mM aspirin for 48 and 72 hours after plating. Aspirin 
treatment led to a more profound induction of apoptosis in 
colon cancer cells harboring a PIK3CA mutation than in 
those with wild-type PIK3CA (Figure 2). We next assessed 
the percentage of cells in each phase of the cell cycle 
within these PIK3CA mutant and wild-type colon cancer 
cells (Figure 3). All PIK3CA-mutant cell lines underwent 
a dose-dependent increase in G0/G1 cell cycle arrest after 
aspirin exposure for 48 and 72 hours. This effect was not 
observed in PIK3CA-wild-type colon cancer cell lines. 
Mutations in PIK3CA oncogene sensitize colon 
cancer cells to aspirin
The PIK3CA c.3140A>G (p.H1047R) and 
c.1633G>A (p.E545K) somatic mutations are commonly 
found in colorectal carcinoma, and were present in the 
colon cancer cells (HCT15 and HCT116, respectively) 
included in the published studies [36, 37]. In order to 
further confirm our findings and ensure that the observed 
PIK3CA-mutant-specific effect was not confounded by 
the genomic backgrounds of the selected cell lines, we 
investigated whether activation of PI3K via knock-in of 
the c.3140A>G (p.H1047R) or c.1633G>A (p.E545K) 
mutation could sensitize a PIK3CA wild-type colon cancer 
cell line to aspirin treatment. Two isogenic cell lines were 
derived from parental SW48 cells, each of which carried 
constitutively active mutant alleles with mutations at 
either c.3140A>G [SW48 (PIK3CA c.3140A>G/+)] or 
c.1633G>A [SW48 (PIK3CA c.1633G>A/+)]. The IC50 
values of each group showed that aspirin treatment of 
isogenic SW48 cells carrying either PIK3CA mutation 
resulted in a statistically significant loss of cell viability 
of up to 47% relative to parental SW48 cells (P = 0.031) 
(Figure 4). 
Table 1: Mutational status of PIK3CA, BRAF, and KRAS in colon cancer cell lines used in the 
current study
Cell line Mutation status*
PIK3CA BRAF KRAS
HCT15 c.1633G>A (p.E545K), 
c.1645G>A (p.D549N)
WT c.38G>A (p.G13D)
HCT116 c.3140A>G (p.H1047R) WT c.38G>A (p.G13D)
HT-29 c.1345C>A (p.P449T) c.1799T>A (p.V600E) WT
LS174T c.3140A>G (p.H1047R) WT c.35G>A (p.G12D)
RKO c.3140A>G (p.H1047R) c.1799T>A (p.V600E) WT
SW948 c.1624G>A (p.E542K) WT c.182A>T (p.Q61L)
T84 c.1624G>A (p.E542K) WT c.38G>A (p.G13D)
CaCo-2 WT WT WT
COLO205 WT c.1799T>A (p.V600E) WT
LOVO WT WT c.38G>A (p.G13D), c.41C>T (p.A14V)
SW48 WT WT WT
SW480 WT WT c.35G>T (p.G12V)
SW620 WT WT c.35G>T (p.G12V)
*Mutation according to the American Type Culture Collection. WT, wild-type.
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DISCUSSION
We conducted this study to provide in vitro 
experimental evidence supporting the recent molecular 
pathological epidemiology studies that suggest tumor 
PIK3CA mutation status as a biomarker to predict benefits 
from aspirin therapy for colorectal cancer [9, 12, 13, 21, 
38]. In this study, we have shown that physiologically 
attainable concentrations of aspirin can exert stronger 
anti-cancer effects on PIK3CA-mutant colon cancer cells 
relative to PIK3CA-wild-type colon cancer cells. 
Our results are consistent with a recent report 
by Zumwalt et al [39] that clarified the relationship 
of PIK3CA mutations in colorectal cancer cells and 
aspirin-induced chemoprevention in vitro and in vivo. In 
that study, eight colon cancer cell lines and engineered 
HCT116 cells with PIK3CA kinase domain mutant allele 
knockout were used to assess the effects of aspirin on 
cell proliferation and cell-cycle distribution. Our current 
study further investigated 13 commonly used colon cancer 
cell lines and two isogenic cell lines with heterozygous 
knock-in of either of PIK3CA mutations c.3140A>G 
(p.H1047R) and c.1633G>A (p.E545K), both of which are 
commonly observed in colorectal carcinoma. In addition, 
aspirin treatment of breast cancer cells carrying mutations 
in PIK3CA at either exon 9 (c.1633G>A) or exon 20 
(c.3140A>G) also resulted in a significant decrease of cell 
viability [40]. 
Although multiple lines of evidence indicate that 
aspirin use after colorectal cancer diagnosis is beneficial, 
Figure 1: Aspirin causes decreased cell viability in PIK3CA-mutant human colon cancer cells. (A) Dose-response curves 
of PIK3CA-mutant (blue lines) or PIK3CA-wild-type (red lines) human colon cancer cells after treatment with increasing concentrations of 
aspirin (0, 0.5, 1, 2, 4, 6, 8, 10 and 12 mM) for 48 and 72 hours. (B) Dose-response curves of human colon cancer cells with BRAF-mutant 
(blue lines) or BRAF-wild-type (red lines) as well as KRAS-mutant (blue lines) or KRAS-wild-type (red lines) after treatment with increasing 
concentrations of aspirin (0, 0.5, 1, 2, 4, 6, 8, 10 and 12 mM) for 48 hours. Percent cell viability is relative to that of DMSO-treated control 
cells. The data shown represent mean ± standard deviation of three replicates. DMSO, dimethyl sulfoxide; WT, wild-type; MUT, mutation.
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the toxicities of therapy, particularly in older patients, have 
limited its use in routine clinical practice [14, 19, 41]. In 2016, 
the USPSTF gave a “B” recommendation (high certainty that 
the net benefit is moderate or moderate certainty that the net 
benefit is moderate or substantial) for routine aspirin use for 
colorectal cancer prophylaxis in U.S. adults between the 
Figure 2: Aspirin treatment results in more apoptosis in PIK3CA-mutant human colon cancer cell lines. PIK3CA-mutant 
human colon cancer cell lines (HCT15, HCT116, and SW948) and PIK3CA-wild-type colorectal cancer cell lines (COLO205, SW480, 
and SW620) were incubated with aspirin (1, 2.5, and 5 mM) or DMSO for 48 and 72 hours. Apoptosis analysis was performed by flow 
cytometry with Annexin V-FITC/PI staining. The percentage of Annexin V-FITC/PI positive cells after aspirin treatment at each dose and 
time point for all cell lines were normalized by DMSO group and compared according PIK3CA status. Student’s t-test was performed to 
determine significance. The data shown represent mean ± standard deviation of three replicates. *P value < 0.05. **P value < 0.01. DMSO, 
dimethyl sulfoxide; MUT, mutation; WT, wild-type.
Figure 3: Aspirin leads to a higher proportion of cells in G0/G1 phase arrest in PIK3CA-mutant human colon cancer cell 
lines. PIK3CA-mutant human colon cancer cell lines (HCT116, HCT15, and SW948) and PIK3CA-wild-type colorectal cancer cell lines 
(COLO205, SW620, and SW480) were incubated with aspirin (0, 1, 2.5, and 5 mM) for 48 and 72 hours. Cell cycle analysis was performed 
by flow cytometry with PI staining. The percentage of G0/G1 phase cells of each aspirin treatment point was normalized by DMSO group 
and was compared according PIK3CA status. Student’s t-test was performed to determine significance. The data shown represent mean ± 
standard deviation of three replicates. *P value < 0.05. **P value < 0.01. DMSO, dimethyl sulfoxide; MUT, mutation; WT, wild-type. 
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ages of 50 and 59 with a greater than 10% 10-year risk of 
cardiovascular events [17]. The USPSTF recommendations 
also highlight the need to clarify the mechanisms by which 
aspirin prevents development of colorectal cancer [18]. There 
are currently several clinical trials underway (including ADD-
ASPIRIN [42], ASCOLT [43], and ASPIRED [44]) that are 
attempting to clarify the association between aspirin use 
and survival after diagnosis of colorectal cancer, as well as 
distinguishing the subgroups of individuals for whom the 
benefits outweigh the harm. Thus, it is essential to confirm 
the efficacy of biomarkers used to predict benefits from 
aspirin therapy through multifaceted approaches, including 
clinical trials and in vitro or in vivo experimental models 
[14]. The present study serves this purpose by improving our 
understanding of the use of tumor PIK3CA mutation status for 
prediction of patient response to aspirin therapy. 
PIK3CA mutations (or PIK3CA amplifications 
[45]) may result in constitutive activation of PI3K and 
the downstream AKT pathway, enhancing PTGS2 activity 
and prostaglandin E2 synthesis and leading to inhibition 
of apoptosis in colorectal cancer cells [11]. Recent in 
vitro and in vivo studies have suggested that aspirin 
may suppress cancer cell growth and induce apoptosis 
through activation of protein kinase A (PRKA, also 
referred to as AMPK), inhibition of MTOR downstream 
signaling, and inhibition of PI3K-induced prostaglandin 
E2 synthesis [46–48]. The present study was designed to 
detect the potency of aspirin therapy in colon cancer cell 
lines according to major somatic driver mutations such 
as PIK3CA, BRAF, and KRAS mutations. The results 
demonstrate that aspirin may selectively cause G0/G1 cell 
cycle arrest, induce apoptosis, and inhibit cell growth 
in human colon cancer cells with PIK3CA mutations in 
vitro. Our findings in the apoptotic and cell cycle assays 
are consistent with the data on the previous in vitro studies 
[39, 40, 47, 48]. The reduced viability of PIK3CA-mutant 
colon cancer cells was also confirmed in colon cancer cells 
containing the heterozygous PIK3CA knock-in mutations 
c.3140A>G (p.H1047R) and c.1633G>A (p.E545K). 
Previous retrospective analyses investigating aspirin use 
in colon cancers according to PIK3CA mutation status 
did not specify which PIK3CA mutations were included 
[10, 12]. The present study is the first to show that the 
isogenic conversion of a PIK3CA-wild-type colon cancer 
cell into a PIK3CA-mutant cell line is sufficient to promote 
sensitization to aspirin. PIK3CA c.3140A>G (p.H1047R) 
and c.1633G>A (p.E545K) mutations are common in 
colorectal carcinomas. Heterozygous knock-in c.3140A>G 
and c.1633G>A mutations in the PIK3CA gene were found 
to activate multiple oncogenic pathways and promote cell 
growth and invasion in vitro for human breast cancer and 
colon cancer cell lines [37, 49]. Notably, breast cancer 
cells carrying a c.3140A>G (p.H1047R) mutation at 
exon 20 were less sensitive to aspirin than those carrying 
a c.1633G>A (p.E545K) mutation at exon 9 [40]. This 
phenomenon may be attributed to differences in the 
aberrant activation of signaling pathways. However, few, 
if any, differences in phenotype were observed according 
to PIK3CA mutation variants.
The relationship between somatic or germline 
genetic variants and the chemopreventive use of aspirin 
is not limited to patients with PIK3CA-mutant colorectal 
cancer. Lizaka and colleagues utilized a genome-wide 
complementary DNA microarray containing 23,040 
genes to analyze the time-dependent alteration of 
gene expression in response to two nonsteroidal anti-
Figure 4: Knock-in of PIK3CA mutations sensitizes colon cancer cells to aspirin. Dose-response curves of parental SW48 
cells (red) and individual knock-in of PIK3CA-activating mutations at either alleles c.3140A>G (p.H1047R) or c.1633G>A (p.E545K) of 
SW48 cells (blue) were treated with aspirin (0, 0.5, 1, 2, 4, 6 and 8 mM) for 48 and 72 hours. Percent cell viability is relative to that of 
DMSO-treated control cells. The data shown represent mean ± standard deviation of three replicates. DMSO, dimethyl sulfoxide; MUT, 
mutation; WT, wild-type.
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inflammatory drugs (NSAIDs), sulindac and aspirin, in 
SNU-C4, SW480, and SW948 colon cancer cell lines [50]. 
Interestingly, they found that PIK3C2A, which belongs 
to the PIK3 family, was down-regulated only in aspirin-
sensitive cells. We previously performed a genome-wide 
analysis of the interactions between single nucleotide 
polymorphisms (SNPs) and aspirin use in relation to colon 
cancer risk, which identified two SNPs on chromosomes 
12 and 15 that differentially correlate with aspirin and 
NSAID effects on colon cancer prevention [51]. One, 
on chromosome 12, is located upstream from PIK3C2G, 
which belongs to the PIK3 family. Combined, these 
findings further support the use of PIK3CA mutation status 
as a biomarker for precision aspirin chemoprevention and 
adjuvant therapy strategies for colon cancer.
Our current study has limitations. As our colon 
cancer cell panel did not include all possible activating 
alterations in PIK3CA, we were unable to elucidate the 
potency of aspirin treatment on colon cancer cells with 
PIK3CA alterations other than the ones examined. In 
addition, our current cancer cell panel was limited to 
immortalized colon cancer cell lines due to the lack 
of reasonable PIK3CA-mutant and PIK3CA-wild-type 
rectal cancer cell line pairs in the American Type Culture 
Collection (ATCC). Taking into account the potential 
heterogeneity of tumor behavior between colon and 
rectal carcinomas, anti-cancer effects of aspirin according 
to PIK3CA mutation status in rectal cancer cells and 
human primary cells should be examined in future 
studies. In the present study, the aspirin concentrations 
utilized in apoptosis and cell cycle analyses are relatively 
high (as high as 5 mM) compared to typical plasma 
concentrations of salicylate (0.19 to 0.63 mM), a major 
metabolite derived from aspirin. Thus, the doses may not 
be attainable through administration of standard doses 
(81 or 325 mg) of aspirin. However, the dose-dependent 
nature of the response to aspirin treatment suggests that 
some effects may be experienced in vivo even at low 
doses. Furthermore, Turturro et al. reported that the 
serum levels of aspirin could safely reach concentrations 
of up to 10 mM [40], indicating that the 5 mM aspirin 
dose is physiologically achievable in humans. Our in 
vitro models did not take into account the critical role 
of the tumor stromal microenvironment. Accumulating 
evidence indicates that regular aspirin use may synergize 
with other immunomodulatory pathways including 
the immune checkpoint blockade in colorectal cancer 
[52–56]. Further investigations are warranted to analyze 
interactions of multiple cell types that exist in the tumor 
microenvironment, and to examine the dual blockade of 
the PTGS2 and immunosuppressive pathways. Another 
drawback is that our current study did not utilize 
functional assays to investigate potential molecular 
mechanisms through which aspirin may exert stronger 
anti-cancer effects on PIK3CA-mutant colon cancer cells 
than PIK3CA-wild-type cells. Nonetheless, our study 
hypothesis was based on human clinical studies [8–13, 57, 
58]. It is important to perform functional studies to explore 
potential mechanisms underlying our findings in the future. 
We point out an important synergism of experimental 
research and molecular pathological epidemiology (MPE) 
research [59–61] as replicating biological complexities 
of human tumors in experimental models is a substantial 
challenge. In addition, it is of particular interest to 
investigate modifying effects of other endogenous and 
exogenous factors (such as diet, lifestyle, microbiota, 
germline genetics, and immunity) on medications (such 
as aspirin) in relation to tumor molecular characteristics 
[4, 6, 7] in integrative pharmaco-MPE research [62, 63] 
in the future.  
In summary, our findings provide valuable in vitro 
data to further support the use of aspirin in patients with 
PIK3CA-mutant colorectal cancer. Further investigations 
into the precise molecular mechanisms associated with 
aspirin treatment of cancers with mutant PIK3CA are 
warranted. 
MATERIALS AND METHODS
Cell lines and culture
A panel of 13 human colon cancer cell lines (CaCo-
2, COLO205, HCT15, HCT116, HT-29, LOVO, LS174T, 
RKO, SW48, SW480, SW620, SW948, and T84) was 
obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA). The mutational gene 
backgrounds of the cell lines were described previously 
[35, 64]. We used X-MAN™ isogenic cell lines, SW48 
(PIK3CA c.1633G>A (p.E545K); Catalog # HD103-001) 
and SW48 (PIK3CA c.3140A>G (p.H1047R); Catalog # 
HD103-005) heterozygous knock-in of PIK3CA activating 
mutations, as well as SW48 parental cells (Catalog # HD 
PAR-006) (Horizon Discovery, Cambridge, MA, USA). 
The parental cell line SW48 was used as a control. All 
cells were cultured in RPMI-1640 (Gibco, Grand Island, 
NY, USA) supplemented with 10% fetal bovine serum 
(Gibco) and 100 U/ml of penicillin-streptomycin in a 
5% CO2 and 95% air humidified atmosphere at 37°C. All 
colon cancer cell lines used in this study passed the STR 
(Short Tandem Repeat) authentication by manufacturers.
Cell proliferation MTS assay
Cells were seeded in 96-well microplates at a 
density of 4x104 cells/ml and cultured overnight; they 
were treated with a range of aspirin (Sigma-Aldrich, 
St. Louis, MO, USA) doses (0, 0.5, 1, 2, 4, 6, 8, 10 and 
12 mM) in dimethyl sulfoxide (DMSO). These doses 
are representative of physiologically attainable plasma 
concentrations as previously reported [40]. Control cells 
received DMSO only. Cell proliferation was assessed after 
48 hours and 72 hours from initial drug exposure using 
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the MTS assay (Promega, Madison, WI, USA) according 
to the manufacturer’s instructions. Cell proliferation is 
directly proportional to the absorbance at 490 nm by a 
formazan product that is bio-reduced from MTS in living 
cells. All experiments were carried out in hexaplicate and 
were repeated at least three times independently.
Apoptosis and cell cycle analysis
The apoptosis levels and cell cycle phase of 
colorectal cancer cells after aspirin exposure were 
assessed as previously described [65, 66]. In brief, for 
apoptosis detection, trypsinized cells were collected gently 
and stained with the Annexin V-fluorescein isothiocyanate 
(FITC)/propidium iodide (PI) Apoptosis Detection kit 
(BD Biosciences, San Jose, CA, USA) according to 
the manufacturer’s protocol. Cell cycle analysis was 
performed using PI staining. Cells fixed with 80% 
ethanol overnight at 4°C were resuspended in phosphate-
buffered saline supplemented with 0.1% Triton X-100 
(Sigma-Aldrich, St Louis, MO, USA), 25 mg/ml PI (BD 
Biosciences) and 0.2 mg/ml RNase A (Sigma-Aldrich), 
then incubated for 30 minutes at room temperature in the 
dark before analysis. Apoptosis and cell cycle phase were 
measured on a FACS Ariall cytometer (BD Biosciences), 
and analysis was performed using FlowJo software 
(FLOWJO, Ashland, OR, USA).
Statistical analysis
Graphpad Prism 6.0 software (Graphpad Software, 
San Diego, CA, USA) was used to describe dose-response 
curves and perform statistical analysis. All data were 
represented for at least three independent experiments. 
The Student’s t-test was used to compare continuous 
measurements in two groups. A P value less than 0.05 was 
considered statistically significant.
Abbreviations
DMSO, dimethyl sulfoxide; IC50, half maximal 
inhibitory concentration; MTS, 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium inner salt; NSAID, nonsteroidal 
anti-inflammatory drug; PI, propidium iodide; PI3K, 
phosphatidylinositol-4,5-bisphosphonate 3-kinase; SNP, 
single nucleotide polymorphism; USPSTF, the U.S. 
Preventive Services Task Force.
Use of standardized official symbols
We use HUGO (Human Genome Organisation)-
approved official symbols (or root symbols) for genes and 
gene products, including AKT, BRAF, CTNNB1, KRAS, 
MTOR, NFKB, PIK3CA, PTGS2, and WNT; all of which 
are described at www.genenames.org. The official symbols 
are italicized to differentiate from non-italicized colloquial 
names that are used along with the official symbols.  This 
format enables readers to familiarize the official symbols 
for genes and gene products together with common 
colloquial names.
Author contributions
M.Gu., C.S.F., Z.R.Q., and S.O. developed the main 
concept and designed the study. M.Gu., A.T.C., C.S.F., 
Z.R.Q., and S.O. wrote grant applications. M.Gu. and 
Z.R.Q. performed experiments. M.Gu., C.S.F., Z.R.Q., and 
S.O. performed data analysis and interpretation. M.Gu. 
and Z.R.Q. drafted the manuscript. All authors discussed 
data and contributed to manuscript review and revision. 
CONFLICTS OF INTEREST
A.T.C. previously served as a consultant for Bayer 
Healthcare, Pfizer Inc., and Aralez Pharmaceuticals. This study 
was not funded by Bayer Healthcare, Pfizer Inc. or Aralez 
Pharmaceuticals. No other conflict of interest exists. The other 
authors declare that they have no conflicts of interest.
FUNDING
This work was supported by U.S. National Institutes 
of Health (NIH) grants (P50 CA127003 to C.S.F.; R01 
CA137178 to A.T.C.; K24 DK098311 to A.T.C.; R35 
CA197735 to S.O.; and K07 CA190673 to R.N.); Nodal 
Award (to S.O.) from the Dana-Farber Harvard Cancer 
Center; and the Project P Fund. M.Gu. was supported by a 
scholarship grant from Chinese Scholarship Council, National 
Natural Science Foundation of China grants (81673607, 
81303235) and a fellowship from Zhejiang Chinese Medical 
University. K.K. was supported by a grant from Program for 
Advancing Strategic International Networks to Accelerate 
the Circulation of Talented Researchers from Japanese 
Society for the Promotion of Science. Z.R.Q. was supported 
by Medical Oncology Translational Grant Program from 
Department of Medical Oncology, Dana-Farber Cancer 
Institute and Harvard Medical School.
REFERENCES
1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester 
RG, Barzi A, Jemal A. Colorectal cancer statistics, 2017. 
CA Cancer J Clin. 2017; 67:177–93.
2. Dienstmann R, Salazar R, Tabernero J. Personalizing colon 
cancer adjuvant therapy: selecting optimal treatments for 
individual patients. J Clin Oncol. 2015; 33:1787–96.
3. Linnekamp JF, Wang X, Medema JP, Vermeulen L. 
Colorectal cancer heterogeneity and targeted therapy: a 
case for molecular disease subtypes. Cancer Res. 2015; 
75:245–9.
Oncotarget87387www.impactjournals.com/oncotarget
 4. Kudryavtseva AV, Lipatova AV, Zaretsky AR, Moskalev AA, 
Fedorova MS, Rasskazova AS, Shibukhova GA, 
Snezhkina AV, Kaprin AD, Alekseev BY, Dmitriev AA, 
Krasnov GS. Important molecular genetic markers of 
colorectal cancer. Oncotarget. 2016; 7:53959–83. https://
doi.org/10.18632/oncotarget.9796.
 5. Patil H, Saxena SG, Barrow CJ, Kanwar JR, Kapat A, 
Kanwar RK. Chasing the personalized medicine dream 
through biomarker validation in colorectal cancer. Drug 
Discov Today. 2017; 22:111–19.
 6. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular 
pathways involved in colorectal cancer: implications for disease 
behavior and prevention. Int J Mol Sci. 2013; 14:16365–85.
 7. Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes 
of colorectal cancer and potential clinical applications. 
Gastroenterol Rep (Oxf). 2015; 3:269–76.
 8. Tougeron D, Sha D, Manthravadi S, Sinicrope FA. Aspirin 
and colorectal cancer: back to the future. Clin Cancer Res. 
2014; 20:1087–94.
 9. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, 
Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, 
Spiegelman D, Cho E, Giovannucci E, et al. Aspirin use 
and risk of colorectal cancer according to BRAF mutation 
status. JAMA. 2013; 309:2563–71.
10. Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, Xia D, Yang J, 
Cai J, Wu Y. Aspirin use after diagnosis but not prediagnosis 
improves established colorectal cancer survival: a meta-
analysis. Gut. 2015; 64:1419–25.
11. Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, 
DeCensi A. PIK3CA Mutation, Aspirin Use after Diagnosis 
and Survival of Colorectal Cancer. A Systematic Review 
and Meta-analysis of Epidemiological Studies. Clin Oncol 
(R Coll Radiol). 2016; 28:317–26.
12. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, 
Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, 
Sun R, Nosho K, Meyerhardt JA, et al. Aspirin use, tumor 
PIK3CA mutation, and colorectal-cancer survival. N Engl J 
Med. 2012; 367:1596–606.
13. Frouws MA, van Herk-Sukel MP, Maas HA, Van de Velde CJ, 
Portielje JE, Liefers GJ, Bastiaannet E. The mortality reducing 
effect of aspirin in colorectal cancer patients: Interpreting the 
evidence. Cancer Treat Rev. 2017; 55:120–27.
14. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: 
the promise of precision chemoprevention. Nat Rev Cancer. 
2016; 16:173–86.
15. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, 
Warlow CP, Meade TW. Effect of daily aspirin on long-term 
risk of death due to cancer: analysis of individual patient 
data from randomised trials. Lancet. 2011; 377:31–41.
16. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, 
Mehta Z. Effect of daily aspirin on risk of cancer metastasis: 
a study of incident cancers during randomised controlled 
trials. Lancet. 2012; 379:1591–601.
17. Bibbins-Domingo K, and U.S. Preventive Services 
Task Force. Aspirin Use for the Primary Prevention of 
Cardiovascular Disease and Colorectal Cancer: U.S. 
Preventive Services Task Force Recommendation 
Statement. Ann Intern Med. 2016; 164:836–45.
18. Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, 
Whitlock EP. Aspirin for the Primary Prevention of 
Cardiovascular Disease and Colorectal Cancer: A Decision 
Analysis for the U.S. Preventive Services Task Force. Ann 
Intern Med. 2016; 164:777–86.
19. Domingo E, Church DN, Sieber O, Ramamoorthy R, 
Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, 
Tomlinson IP, Midgley R. Evaluation of PIK3CA 
mutation as a predictor of benefit from nonsteroidal anti-
inflammatory drug therapy in colorectal cancer. J Clin 
Oncol. 2013; 31:4297–305.
20. Gray RT, Cantwell MM, Coleman HG, Loughrey MB, 
Bankhead P, McQuaid S, O’Neill RF, Arthur K, Bingham V, 
McGready C, Gavin AT, Cardwell CR, Johnston BT, et 
al. Evaluation of PTGS2 Expression, PIK3CA Mutation, 
Aspirin Use and Colon Cancer Survival in a Population-
Based Cohort Study. Clin Transl Gastroenterol. 2017; 8:e91.
21. Murphy C, Turner N, Wong HL, Sinnathamby M, Tie J, 
Lee B, Desai J, Skinner I, Christie M, Hutchinson R, Lunke 
S, Waring P, Gibbs P, et al. Examining the impact of regular 
aspirin use and PIK3CA mutations on survival in stage 2 
colon cancer. Intern Med J. 2017; 47:88–98.
22. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, 
Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, 
Huttenhower C, Chan AT, Giovannucci E, Fuchs C, et al. 
Assessment of colorectal cancer molecular features along 
bowel subsites challenges the conception of distinct 
dichotomy of proximal versus distal colorectum. Gut. 2012; 
61:847–54.
23. Rosty C, Young JP, Walsh MD, Clendenning M, 
Sanderson K, Walters RJ, Parry S, Jenkins MA, Win AK, 
Southey MC, Hopper JL, Giles GG, Williamson EJ, et al. 
PIK3CA activating mutation in colorectal carcinoma: 
associations with molecular features and survival. PLoS 
One. 2013; 8:e65479.
24. Vogelaar F, Van Erning F, Reimers M, Van Der Linden J, 
Pruijt J, Van Den Brule A, Bosscha K. The prognostic value 
of Microsatellite Instability, KRAS, BRAF and PIK3CA 
mutations in stage II colon cancer patients. Mol Med. 2015; 
17:1–26.
25. Phipps AI, Ahnen DJ, Cheng I, Newcomb PA, Win AK, 
Burnett T. PIK3CA Somatic Mutation Status in Relation 
to Patient and Tumor Factors in Racial/Ethnic Minorities 
with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 
2015; 24:1046–51.
26. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, 
Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis 
KM, Fuchs CS, Ogino S. Specific mutations in KRAS codons 
12 and 13, and patient prognosis in 1075 BRAF wild-type 
colorectal cancers. Clin Cancer Res. 2012; 18:4753–63.
27. Manceau G, Marisa L, Boige V, Duval A, Gaub MP, 
Milano G, Selves J, Olschwang S, Jooste V, le Legrain M, 
Oncotarget87388www.impactjournals.com/oncotarget
Lecorre D, Guenot D, Etienne-Grimaldi MC, et al. PIK3CA 
mutations predict recurrence in localized microsatellite 
stable colon cancer. Cancer Med. 2015; 4:371–82.
28. Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, 
Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, 
Peng S, Bass AJ, et al. Analyses of clinicopathological, 
molecular, and prognostic associations of KRAS codon 61 
and codon 146 mutations in colorectal cancer: cohort study 
and literature review. Mol Cancer. 2014; 13:135.
29. Cathomas G. PIK3CA in Colorectal Cancer. Front Oncol. 
2014; 4:35.
30. Leystra AA, Deming DA, Zahm CD, Farhoud M, Olson TJ, 
Hadac JN, Nettekoven LA, Albrecht DM, Clipson L, 
Sullivan R, Washington MK, Torrealba JR, Weichert JP, 
et al. Mice expressing activated PI3K rapidly develop 
advanced colon cancer. Cancer Res. 2012; 72:2931–6.
31. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, 
Delong L, Cheong I, Rago C, Huso DL, Lengauer C, 
Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA 
promotes cell growth and invasion of human cancer cells. 
Cancer Cell. 2005; 7:561–73.
32. Papadatos-Pastos D, Rabbie R, Ross P, Sarker D. The role 
of the PI3K pathway in colorectal cancer. Crit Rev Oncol 
Hematol. 2015; 94:18–30.
33. Wang DZ, Wang HB, Shi Q, Katkuri S, Walhi W, 
Desvergne B, Das SK, Dey SK, DuBois RN. Prostaglandin 
E-2 promotes colorectal adenoma growth via transactivation 
of the nuclear peroxisome proliferator-activated receptor 
delta. Cancer Cell. 2004; 6:285–95.
34. Guo XN, Rajput A, Rose R, Hauser J, Beko A, 
Kuropatwinski K, Levea C, Hoffman RM, Brattain NG, 
Wang J. Mutant PIK3CA-bearing colon cancer cells display 
increased metastasis in an orthotopic model. Cancer Res. 
2007; 67:5851–58.
35. Barretina J, Caponigro G, Stransky N, Venkatesan K, 
Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, 
Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer 
Cell Line Encyclopedia enables predictive modelling of 
anticancer drug sensitivity. Nature. 2012; 483:603–7.
36. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, 
Garraway LA, Golub TR, Meyerson M, Gabriel SB, 
Lander ES, Getz G. Discovery and saturation analysis 
of cancer genes across 21 tumour types. Nature. 2014; 
505:495–501.
37. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, 
Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, 
Markowitz S, Kinzler KW, et al. High frequency of 
mutations of the PIK3CA gene in human cancers. Science. 
2004; 304:554.
38. Mei ZB, Duan CY, Li CB, Cui L, Ogino S. Prognostic 
role of tumor PIK3CA mutation in colorectal cancer: a 
systematic review and meta-analysis. Ann Oncol. 2016; 
27:1836–48.
39. Zumwalt TJ, Wodarz D, Komarova NL, Toden S, Turner 
J, Cardenas J, Burn J, Chan AT, Boland CR, Goel A. 
Aspirin-Induced Chemoprevention and Response Kinetics 
Are Enhanced by PIK3CA Mutations in Colorectal Cancer 
Cells. Cancer Prev Res (Phila). 2017; 10:208–18.
40. Turturro SB, Najor MS, Ruby CE, Cobleigh MA, 
Abukhdeir AM. Mutations in PIK3CA sensitize breast 
cancer cells to physiologic levels of aspirin. Breast Cancer 
Res Treat. 2016; 156:33–43.
41. Chan AT, Ladabaum U. Where Do We Stand With Aspirin 
for the Prevention of Colorectal Cancer? The USPSTF 
Recommendations. Gastroenterology. 2016; 150:14–8.
42. Coyle C, Cafferty FH, Rowley S, MacKenzie M, 
Berkman L, Gupta S, Pramesh CS, Gilbert D, Kynaston H, 
Cameron D, Wilson RH, Ring A, Langley RE, and Add-
Aspirin investigators. A phase III, double-blind, placebo 
controlled, randomised trial assessing the effects of aspirin 
on disease recurrence and survival after primary therapy 
in common non-metastatic solid tumours. Contemp Clin 
Trials. 2016; 51:56–64.
43. Ali R, Toh HC, Chia WK, and ASCOLT Trial Investigators. 
The utility of Aspirin in Dukes C and High Risk Dukes B 
Colorectal cancer--the ASCOLT study: study protocol for a 
randomized controlled trial. Trials. 2011; 12:261.
44. Drew DA, Chin SM, Gilpin KK, Parziale M, Pond E, 
Schuck MM, Stewart K, Flagg M, Rawlings CA, 
Backman V, Carolan PJ, Chung DC, Colizzo FP 3rd, et al. 
ASPirin Intervention for the REDuction of colorectal 
cancer risk (ASPIRED): a study protocol for a randomized 
controlled trial. Trials. 2017; 18:50.
45. Jehan Z, Bavi P, Sultana M, Abubaker J, Bu R, Hussain A, 
Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari LH, 
Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Frequent 
PIK3CA gene amplification and its clinical significance in 
colorectal cancer. J Pathol. 2009; 219:337–46.
46. Claudius AK, Kankipati CS, Kilari RS, Hassan S, Guest K, 
Russell ST, Perry CJ, Stark LA, Nicholl ID. Identification 
of aspirin analogues that repress NF-kappaB signalling and 
demonstrate anti-proliferative activity towards colorectal 
cancer in vitro and in vivo. Oncol Rep. 2014; 32:1670–80.
47. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, 
Sakamoto K, Alessi DR, Dunlop MG. Aspirin inhibits 
mTOR signaling, activates AMP-activated protein 
kinase, and induces autophagy in colorectal cancer cells. 
Gastroenterology. 2012; 142:1504–15.
48. Jung YR, Kim EJ, Choi HJ, Park JJ, Kim HS, Lee YJ, 
Park MJ, Lee M. Aspirin Targets SIRT1 and AMPK to 
Induce Senescence of Colorectal Carcinoma Cells. Mol 
Pharmacol. 2015; 88:708–19.
49. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann 
SM, Pearline RV, Cantley LC, Brugge JS. Breast cancer-
associated PIK3CA mutations are oncogenic in mammary 
epithelial cells. Cancer Res. 2005; 65:10992–1000.
50. Iizaka M, Furukawa Y, Tsunoda T, Akashi H, Ogawa M, 
Nakamura Y. Expression profile analysis of colon cancer 
cells in response to sulindac or aspirin. Biochem Biophys 
Res Commun. 2002; 292:498–512.
Oncotarget87389www.impactjournals.com/oncotarget
51. Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, 
Baron JA, Berndt SI, Brenner H, Butterbach K, Caan BJ, 
Campbell PT, Carlson CS, et al, and CCFR, and GECCO. 
Association of aspirin and NSAID use with risk of 
colorectal cancer according to genetic variants. JAMA. 
2015; 313:1133–42.
52. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, 
Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, 
Shokat KM, McCormick F. PIK3CA cooperates with other 
phosphatidylinositol 3’-kinase pathway mutations to effect 
oncogenic transformation. Cancer Res. 2008; 68:8127–36.
53. Ma X, Aoki T, Tsuruyama T, Narumiya S. Definition 
of Prostaglandin E2-EP2 Signals in the Colon Tumor 
Microenvironment That Amplify Inflammation and Tumor 
Growth. Cancer Res. 2015; 75:2822–32.
54. Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, 
Song M, Mima K, Kosumi K, Liu L, Shi Y, da Silva A, Gu M, 
et al. Aspirin Use and Colorectal Cancer Survival According 
to Tumor CD274 (Programmed Cell Death 1 Ligand 1) 
Expression Status. J Clin Oncol. 2017; 35:1836–44.
55. Cao Y, Nishihara R, Qian ZR, Song M, Mima K, Inamura K, 
Nowak JA, Drew DA, Lochhead P, Nosho K, Morikawa T, 
Zhang X, Wu K, et al. Regular Aspirin Use Associates With 
Lower Risk of Colorectal Cancers With Low Numbers of 
Tumor-Infiltrating Lymphocytes. Gastroenterology. 2016; 
151:879–92.e4.
56. Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, 
Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, 
Quezada SA, Sahai E, Reis e Sousa C. Cyclooxygenase-
Dependent Tumor Growth through Evasion of Immunity. 
Cell. 2015; 162:1257–70.
57. Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van 
de Velde CJ. Biomarkers in precision therapy in colorectal 
cancer. Gastroenterol Rep (Oxf). 2013; 1:166–83.
58. Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van 
Vlierberghe RL, Lemmens VE, van Herk-Sukel MP, van 
Wezel T, Fodde R, Kuppen PJ, Morreau H, van de Velde CJ, 
Liefers GJ. Expression of HLA class I antigen, aspirin use, 
and survival after a diagnosis of colon cancer. JAMA Intern 
Med. 2014; 174:732–9.
59. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular 
pathological epidemiology of colorectal neoplasia: an 
emerging transdisciplinary and interdisciplinary field. Gut. 
2011; 60:397–411.
60. Ogino S, Nishihara R, VanderWeele TJ, Wang M, Nishi A, 
Lochhead P, Qian ZR, Zhang X, Wu K, Nan H, Yoshida K, 
Milner DA Jr, Chan AT, et al. Review Article: The Role 
of Molecular Pathological Epidemiology in the Study 
of Neoplastic and Non-neoplastic Diseases in the Era of 
Precision Medicine. Epidemiology. 2016; 27:602–11.
61. Rescigno T, Micolucci L, Tecce MF, Capasso A. Bioactive 
Nutrients and Nutrigenomics in Age-Related Diseases. 
Molecules. 2017; 22:e105.
62. Nishihara R, VanderWeele TJ, Shibuya K, Mittleman MA, 
Wang M, Field AE, Giovannucci E, Lochhead P, Ogino S. 
Molecular pathological epidemiology gives clues to 
paradoxical findings. Eur J Epidemiol. 2015; 30:1129–35.
63. Hamada T, Keum N, Nishihara R, Ogino S. Molecular 
pathological epidemiology: new developing frontiers of 
big data science to study etiologies and pathogenesis. J 
Gastroenterol. 2017; 52:265–75.
64. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes 
M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic 
features of 24 colon cancer cell lines. Oncogenesis. 2013; 
2:e71.
65. Yue W, Zheng X, Lin Y, Yang CS, Xu Q, Carpizo D, 
Huang H, DiPaola RS, Tan XL. Metformin combined with 
aspirin significantly inhibit pancreatic cancer cell growth 
in vitro and in vivo by suppressing anti-apoptotic proteins 
Mcl-1 and Bcl-2. Oncotarget. 2015; 6:21208–24. https://doi.
org/10.18632/oncotarget.4126.
66. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, 
Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, 
Altabef A, Perez-Atayde A, Wong KK, Yuan GC, et al. 
CDK7 inhibition suppresses super-enhancer-linked 
oncogenic transcription in MYCN-driven cancer. Cell. 
2014; 159:1126–39.
